Read by QxMD icon Read

EJNMMI Research

Mark R Battle, Lovena Chedumbarum Pillay, Val J Lowe, David Knopman, Bradley Kemp, Christopher C Rowe, Vincent Doré, Victor L Villemagne, Christopher J Buckley
INTRODUCTION: A standardised method for quantifying β-amyloid PET tracers would allow comparison across different tracers and different sites. The development of the Centiloid scale has aimed to achieve this, applying a common scale to better aid the diagnosis and prognosis of Alzheimer's disease (AD) and to monitor anti-amyloid therapeutic interventions. Here, we apply the Centiloid method to [18 F]flutemetamol and [11 C]PiB (PiB, Pittsburgh compound B) PET images and derive the scaling factor to express their binding in Centiloids...
December 5, 2018: EJNMMI Research
Lutz Tellmann, Hans Herzog, Frank Boers, Christoph Lerche, N Jon Shah
INTRODUCTION: Due to the high noise emission generated by the gradients in magnetic resonance imaging (MRI), an efficient method of noise protection is mandatory. In addition to providing hearing protection, appropriate headphone systems also serve to facilitate communication between the operator and the patient. However, in combined PET-MR devices, use of common pneumatic headphones, as delivered by the manufacturer, is problematic due to the potential generation of attenuation artefacts in the PET measurement...
December 3, 2018: EJNMMI Research
Teele Kuusk, Maarten L Donswijk, Renato A Valdés Olmos, Roderick E De Bruijn, Oscar R Brouwer, Kees Hendricksen, Simon Horenblas, Katarzyna Jóźwiak, Warner Prevoo, Henk G Van Der Poel, Bas W G Van Rhijn, Esther M Wit, Axel Bex
BACKGROUND: Sentinel lymph node biopsy (SLNB) after intratumoral injection of 99m Tc labeled nanocolloid and imaging with scintigraphy and SPECT/CT in renal tumors is feasible. However, sentinel lymph node (SN) non-detection rate with scintigraphy and SPECT/CT is high. The aim of the study was to determine factors affecting non-visualization (NV) of SN imaging in renal tumors. Seventy-eight patients with cT1-3 renal tumors received intratumoral injection of 225 MBq 99m Tc-labeled nanocolloid 1 day before (partial) nephrectomy...
December 3, 2018: EJNMMI Research
Renaud Ciappuccini, Cédric Desmonts, Idlir Licaj, Cécile Blanc-Fournier, Stéphane Bardet, Nicolas Aide
BACKGROUND: 18 FDG PET/CT is crucial before neck surgery for nodal recurrence localization in iodine-refractory differentiated or poorly differentiated thyroid cancer (DTC/PDTC). A dedicated head-and-neck (HN) acquisition performed with a thin matrix and point-spread-function (PSF) modelling in addition to the whole-body PET study has been shown to improve the detection of small cancer deposits. Different protocols have been reported with various acquisition times of HN PET/CT. We aimed to compare two reconstruction algorithms for disease detection and to determine the optimal acquisition time per bed position using the Siemens Biograph6 with extended field-of-view...
December 3, 2018: EJNMMI Research
Lore Santoro, Erick Mora-Ramirez, Dorian Trauchessec, Soufiane Chouaf, Pierre Eustache, Jean-Pierre Pouget, Pierre-Olivier Kotzki, Manuel Bardiès, Emmanuel Deshayes
BACKGROUND: This study's aim was to develop our dosimetric methodology using a commercial workstation for the routine evaluation of the organs at risk during peptide receptor radionuclide therapy (PRRT) with 177 Lu. METHODS: First, planar and SPECT sensitivity factors were determined on phantoms. The reconstruction parameters were optimized by SPECT/CT image acquisition using a NEMA IEC phantom containing a 500 ml bottle of 177 Lu, to simulate a kidney. The recovery coefficients were determined on various phantoms...
November 29, 2018: EJNMMI Research
Pontus Plavén-Sigray, Granville James Matheson, Zsolt Cselényi, Aurelija Jucaite, Lars Farde, Simon Cervenka
PURPOSE: The PET radioligand (R)-[11 C]PK11195 is used to quantify the 18-kDa translocator protein (TSPO), a marker for glial activation. Since there is no brain region devoid of TSPO, an arterial input function (AIF) is ideally required for quantification of binding. However, obtaining an AIF is experimentally demanding, is sometimes uncomfortable for participants, and can introduce additional measurement error during quantification. The objective of this study was to perform an evaluation of the test-retest reliability and convergent validity of techniques used for quantifying (R)-[11 C]PK11195 binding without an AIF in clinical studies...
November 29, 2018: EJNMMI Research
Ellen C de Heer, Adrienne H Brouwers, Ronald Boellaard, Wim J Sluiter, Gilles F H Diercks, Geke A P Hospers, Elisabeth G E de Vries, Mathilde Jalving
BACKGROUND: Metastatic melanoma patients can have durable responses to systemic therapy and even long-term survival. However, a large subgroup of patients does not benefit. Tumour metabolic alterations may well be involved in the efficacy of both targeted and immunotherapy. Knowledge on in vivo tumour glucose uptake and its heterogeneity in metastatic melanoma may aid in upfront patient selection for novel (concomitant) metabolically targeted therapies. The aim of this retrospective study was to provide insight into quantitative 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT) parameters and corresponding intra- and inter-patient heterogeneity in tumour 18 F-FDG uptake among metastatic melanoma patients...
November 20, 2018: EJNMMI Research
Elyse Colard, Sarkis Delcourt, Laetitia Padovani, Sébastien Thureau, Arthur Dumouchel, Pierrick Gouel, Justine Lequesne, Bardia Farman Ara, Pierre Vera, David Taïeb, Isabelle Gardin, Dominique Barbolosi, Sébastien Hapdey
BACKGROUND: In FDG-PET, SUV images are hampered by large potential biases. Our aim was to develop an alternative method (ParaPET) to generate 3D kinetic parametric FDG-PET images easy to perform in clinical oncology. METHODS: The key points of our method are the use of a new error model of PET measurement extracted from a late dynamic PET acquisition of 15 min, centered over the lesion and an image-derived input function (IDIF). The 15-min acquisition is reconstructed to obtain five images of FDG mean activity concentration and images of its variance to model errors of PET measurement...
November 15, 2018: EJNMMI Research
Susanna Jakobson Mo, Jan Axelsson, Lars Jonasson, Anne Larsson, Mattias J Ögren, Margareta Ögren, Andrea Varrone, Linda Eriksson, David Bäckström, Sara Af Bjerkén, Jan Linder, Katrine Riklund
BACKGROUND: Dopamine transporter (DAT) imaging may be of diagnostic value in patients with clinically suspected parkinsonian disease. The purpose of this study was to compare the diagnostic performance of DAT imaging with positron emission computed tomography (PET), using the recently developed, highly DAT-selective radiopharmaceutical [18 F]FE-PE2I (FE-PE2I), to the commercially available and frequently used method with [123 I]FP-CIT (FP-CIT) single-photon emission computed tomography (SPECT) in early-stage idiopathic parkinsonian syndrome (PS)...
November 15, 2018: EJNMMI Research
Niklas Verloh, Ingo Einspieler, Kirsten Utpatel, Karin Menhart, Stefan Brunner, Frank Hofheinz, Jörg van den Hoff, Philipp Wiggermann, Matthias Evert, Christian Stroszczynski, Dirk Hellwig, Jirka Grosse
OBJECTIVE: The aim of this study was to assess the value of 18 F-FDG PET/CT for quantitative assessment of hepatic metabolism in patients with different stages of liver fibrosis/cirrhosis. MATERIALS AND METHODS: 18 F-FDG PET/CT scans of 37 patients either with or without liver fibrosis/cirrhosis, classified according to the METAVIR score (F0-F4) obtained from histopathological analysis of liver specimen, were analyzed retrospectively and classified as follows: no liver fibrosis (F0, n = 6), mild liver fibrosis (F1, n = 11), advanced liver fibrosis (F2, n = 6), severe liver fibrosis (F3, n = 5), and liver cirrhosis (F4, n = 11)...
November 9, 2018: EJNMMI Research
Jun Zhang, Piotr Maniawski, Michael V Knopp
BACKGROUND: The first solid-state silicon photomultiplier (SiPM) digital photon counting (DPC) clinical PET/CT system was introduced by Philips in recent years. The system differs from other SiPM-based PET/CT systems and uses lutetiumyttrium oxyorthosilicate (LYSO) scintillators directly coupled with their own individual SiPM DPC detectors eliminating the need for Anger-logic positioning decoding. We evaluated the system performance, characteristics, and stability of the next generation DPC clinical PET/CT based on NEMA NU2-2012 tests, NEMA NU2-2018 test (timing resolution) and human studies...
November 6, 2018: EJNMMI Research
Katharina Lückerath, Liu Wei, Wolfgang P Fendler, Susan Evans-Axelsson, Andreea D Stuparu, Roger Slavik, Christine E Mona, Jeremie Calais, Matthew Rettig, Robert E Reiter, Ken Herrmann, Caius G Radu, Johannes Czernin, Matthias Eiber
BACKGROUND: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a promising yet not curative approach in castration-resistant (CR) prostate cancer (PC). Rational combination therapies may improve treatment efficacy. Here, we explored the effect of androgen receptor blockade (ARB) on PSMA expression visualized by PET and its potential additive effect when combined with 177 Lu-PSMA RLT in a mouse model of prostate cancer. METHODS: Mice bearing human CRPC (C4-2 cells) xenografts were treated with 10 mg/kg enzalutamide (ENZ), with 50 mg/kg bicalutamide (BIC), or vehicle (control) for 21 days...
October 29, 2018: EJNMMI Research
Sarah Pfaff, Tina Nehring, Verena Pichler, Jens Cardinale, Markus Mitterhauser, Marcus Hacker, Wolfgang Wadsak
BACKGROUND: HEPES is a favorable buffer for 68 Ga-complexations in radiochemical laboratories. The drawback of this buffer is its prescribed limit of 200 μg per recommended application volume in the final formulation. Currently, a TLC test according to the European Pharmacopoeia (Ph. Eur.) has to be performed for quantification, but this analysis suffers from low reliability and reproducibility and is based on a subjective, semi-quantitative visual evaluation. In this study, the TLC method according to the Ph...
October 23, 2018: EJNMMI Research
Sho Furuya, Osamu Manabe, Hiroshi Ohira, Kenji Hirata, Tadao Aikawa, Masanao Naya, Ichizo Tsujino, Kazuhiro Koyanagawa, Toshihisa Anzai, Noriko Oyama-Manabe, Tohru Shiga
BACKGROUND: Cardiac sarcoidosis (CS) is a rare but potentially life-threatening disease that causes conduction disturbance, systolic dysfunction, and, most notably, sudden cardiac death. 18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) plays important roles not only in diagnosing CS but also in evaluating the effects of anti-inflammatory therapy. A volume-based analysis of parameters measured by FDG PET, so-called cardiac metabolic volume (CMV), has emerged as a new assessment tool...
October 5, 2018: EJNMMI Research
Antoine Verger, Eric Malbos, Emmanuelle Reynaud, Pierre Mallet, Daniel Mestre, Jean-Marie Pergandi, Stéphanie Khalfa, Eric Guedj
BACKGROUND: The aim of this pilot study is to investigate the impact of virtual reality exposure therapy (VRET) on brain metabolism and connectivity. Eighteen patients with acrophobia were assessed by an 18 F-FDG PET scan sensitized by virtual exposure before treatment, and nine of them were assessed again after eight sessions of VRET. Statistical Parametric Mapping was used to study the correlations between metabolism and pretherapeutic clinical scores and to compare metabolism before and after VRET (p voxel < 0...
October 1, 2018: EJNMMI Research
Fayçal Ben Bouallègue, Denis Mariano-Goulart, Denis Agostini, Alain Manrique
BACKGROUND: We investigated the feasibility of left ventricular (LV) and right ventricular (RV) volume and function estimation using a first-pass gated 15 O-water PET. This prospective study included 19 patients addressed for myocardial perfusion reserve assessment using 15 O-water PET. PET data were acquired at rest and after regadenoson stress, and gated first-pass images were reconstructed over the time range corresponding to tracer first-pass through the cardiac cavities and post-processed using TomPool software; LV and RV were segmented using a semi-automated 4D immersion algorithm...
September 17, 2018: EJNMMI Research
Lena Vomacka, Marcus Unterrainer, Adrien Holzgreve, Erik Mille, Astrid Gosewisch, Julia Brosch, Sibylle Ziegler, Bogdana Suchorska, Friedrich-Wilhelm Kreth, Jörg-Christian Tonn, Peter Bartenstein, Nathalie Lisa Albert, Guido Böning
BACKGROUND: Glioma grading with dynamic 18 F-FET PET (0-40 min p.i.) is typically performed by analysing the mean time-activity curve of the entire tumour or a suspicious area within a heterogeneous tumour. This work aimed to ensure a reader-independent glioma characterisation and identification of aggressive sub-volumes by performing a voxel-based analysis with diagnostically relevant kinetic and static 18 F-FET PET parameters. One hundred sixty-two patients with a newly diagnosed glioma classified according to histologic and molecular genetic properties were evaluated...
September 10, 2018: EJNMMI Research
Tibor Vag, Katja Steiger, Andreas Rossmann, Ulrich Keller, Aurelia Noske, Peter Herhaus, Johannes Ettl, Markus Niemeyer, Hans-Jürgen Wester, Markus Schwaiger
BACKGROUND: CXCR4 is a chemokine receptor frequently overexpressed in invasive breast cancer that has been shown to play a major role in signaling pathways involved in metastasis. The aim of this retrospective analysis was to assess the diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer using the recently introduced CXCR4-targeted PET probe 68 Ga-Pentixafor. RESULTS: Thirteen patients with first diagnosis of breast cancer, four patients with recurrent disease after primary breast cancer, and one patient with axillary lymph node metastasis of unknown primary underwent CXCR4-targeted PET imaging using 68 Ga-Pentixafor...
September 6, 2018: EJNMMI Research
Erica Silvestri, Valentina Scolozzi, Gaia Rizzo, Luca Indovina, Marco Castellaro, Maria Vittoria Mattoli, Paolo Graziano, Giuseppe Cardillo, Alessandra Bertoldo, Maria Lucia Calcagni
BACKGROUND: The validation of the most appropriate compartmental model that describes the kinetics of a specific tracer within a specific tissue is mandatory before estimating quantitative parameters, since the behaviour of a tracer can be different among organs and diseases, as well as between primary tumours and metastases. The aims of our study were to assess which compartmental model better describes the kinetics of 18 F-Fluorodeoxygluxose(18 F-FDG) in primary lung cancers and in metastatic lymph nodes; to evaluate whether quantitative parameters, estimated using different innovative technologies, are different between lung cancers and lymph nodes; and to evaluate the intra-tumour inhomogeneity...
August 29, 2018: EJNMMI Research
Daphne Merel Valerie Huizing, Berlinda Jantina de Wit-van der Veen, Marcel Verheij, Marcellus Petrus Maria Stokkel
BACKGROUND: The main challenge for systemic radiation therapy using radiopharmaceuticals (SRT) is to optimise the dose delivered to the tumour, while minimising normal tissue irradiation. Dosimetry could help to increase therapy response and decrease toxicity after SRT by individual treatment planning. Peptide receptor radionuclide therapy (PRRT) is an accepted SRT treatment option for irresectable and metastatic neuroendocrine tumours (NET). However, dosimetry in PRRT is not routinely performed, mainly due to the lack of evidence in literature and clinical implementation difficulties...
August 29, 2018: EJNMMI Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"